Cite

HARVARD Citation

    Dizon, D. et al. (2018). Complete Remission Following Pembrolizumab in a Woman with Mismatch Repair‐Deficient Endometrial Cancer and a Germline BRCA1 Mutation. Oncologist. pp. 650-653. [Online]. 
  
Back to record